Clinical trial · no report yet · Phase 2
ETNA
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
- NCT06078384 ↗
- Recruiting
- UNICANCER
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Pembrolizumab 25 mg/ml; Paclitaxel injection
- Arms
- Cohort 1-Pembrolizumab plus Paclitaxel · Experimental
- Cohort 2-Observation · No intervention
- Enrollment
- 354 (estimated)
- Primary outcomes
- Distant disease-free survival (DDFS)
- Sponsor
- UNICANCER with MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca
- Start
- Dec 27, 2024
- Primary completion
- Jan 1, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06078384 · updated Jul 24, 2026